Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Debiopharm

Status and phase

Completed

Phase 1

Conditions

Lymphoma

Cancer

Solid Tumors

Malignancy

Treatments

Drug: Debio 1143 (AT-406)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01078649

Debio 1143-101 (AT-406-CS-001)

Details and patient eligibility

About

The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans. This study is also designed to measure how much Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143 (AT-406) interacts with proteins related to cancer that the drug is targeted to affect (pharmacodynamics).

Full description

Ascenta Therapeutics, Inc. is conducting a clinical trial of the compound Debio 1143 (AT-406), a small molecule second mitochondria-derived activator of caspase C (Smac) mimetic. In vivo and in vitro studies have demonstrated that Debio 1143 (AT-406) induces cell death in several tumor models by inhibiting XIAP (X linked IAP), cIAP-1 (cellular IAP-1) and cIAP-2 (cellular IAP-2), thus releasing initiator and effector caspases to promote apoptosis. This protocol is a Phase I, dose-escalation, open-label, multi-center study conducted in patients with advanced solid tumors and lymphomas to evaluate the safety, tolerability and pharmacology of Debio 1143 (AT-406) in humans when administered orally.

Enrollment

51 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed solid tumor or lymphoma;
Locally advanced or metastatic disease for which no life prolonging therapy is available and no standard therapy is judged appropriate by the investigator;
Eastern Cooperative Oncology Group Performance Status ≤ 1;
Adequate hematologic function as indicated by, ANC ≥ 1,500/mm3, Hgb >9.0 g/dL, platelet count ≥ 100,000/mm3
Adequate renal and liver function as indicated by serum creatinine ≤ 1.0 x ULN or creatinine clearance of > 60 cc/min, serum albumin ≥ 3.0 gm/dL, total bilirubin < 1.0 x ULN, AST and ALT ≤ 2.5 x ULN ; Alkaline phosphatase ≤2.5 x ULN
Negative Hepatitis B and Hepatitis C testing;
QTc interval ≤450ms.

Exclusion criteria

Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry. Patients who have received prior radiotherapy must have discontinued steroids for 14 days prior to study entry and be clinically stable;
Not recovered to ≤ Grade 1 toxicity from prior radiotherapy or chemotherapy agents;
Use or requirement for use of aspirin or aspirin containing products with >81 mg of aspirin per day;
History of gastrointestinal bleeding within 1 year;
History of diabetes mellitus requiring treatment with oral agents or insulin;
Active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation;
Known or suspected Wilson's Disease, or other conditions that affect copper accumulation or regulation;
Prior treatment with IAP inhibitors.